Direct  	Direct  	 NNP	O
Flow  	Flow  	 NNP	B-NP
Medical  	Medical  	 NNP	I-NP
valve  	valve  	 VBD	I-NP
To  	To  	 TO	O
study  	study  	 VB	O
the  	the  	 DT	O
feasibility  	feasibility  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
non-metallic 	non-metallic 	 JJ	B-NP
,  	,  	 ,	O
repositionable  	repositionable  	 NN	B-NP
and  	and  	 CC	O
retrievable  	retrievable  	 JJ	O
percutaneous  	percutaneous  	 JJ	O
Direct  	Direct  	 NNP	B-NP
Flow  	Flow  	 NNP	I-NP
Medical  	Medical  	 NNP	I-NP
( 	( 	 -LRB-	O
DFM 	DFM 	 NNP	B-NP
)  	)  	 -RRB-	O
aortic  	aortic  	 JJ	B-NP
valve 	valve 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
first-generation  	first-generation  	 JJ	B-NP
( 	( 	 -LRB-	O
22  	22  	 CD	O
Fr 	Fr 	 NNP	B-NP
)  	)  	 -RRB-	O
DFM  	DFM  	 NNP	B-NP
valve  	valve  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
prospective  	prospective  	 JJ	B-NP
non-randomised  	non-randomised  	 JJ	I-NP
trial  	trial  	 NN	I-NP
in  	in  	 IN	O
31  	31  	 CD	O
high-risk  	high-risk  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
severe  	severe  	 JJ	O
symptomatic  	symptomatic  	 JJ	B-NP
aortic  	aortic  	 JJ	I-NP
stenosis 	stenosis 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
procedural  	procedural  	 JJ	B-NP
success  	success  	 NN	I-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
71 	71 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
30-day  	30-day  	 JJ	O
mortality  	mortality  	 NN	O
12.9 	12.9 	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
Survival  	Survival  	 NN	O
at  	at  	 IN	O
three  	three  	 CD	O
years  	years  	 NNS	O
was  	was  	 VBD	O
60 	60 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
all  	all  	 DT	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
none 	none 	 NN	B-NP
/ 	/ 	 FW	I-NP
trace  	trace  	 FW	I-NP
aortic  	aortic  	 FW	I-NP
regurgitation  	regurgitation  	 FW	I-NP
at  	at  	 IN	O
three  	three  	 CD	O
years 	years 	 NNS	O
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
experience 	experience 	 NN	O
,  	,  	 ,	O
an  	an  	 DT	O
18  	18  	 CD	O
Fr  	Fr  	 JJ	B-NP
device  	device  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
developed  	developed  	 VBN	O
with  	with  	 IN	O
several  	several  	 JJ	O
important  	important  	 JJ	O
revisions  	revisions  	 NNS	O
to  	to  	 TO	O
improve  	improve  	 VB	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
procedure 	procedure 	 NN	O
.  	.  	 .	O
Currently 	Currently 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
being  	being  	 VBG	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
multicentre  	multicentre  	 JJ	B-NP
non-randomised  	non-randomised  	 JJ	I-NP
trial  	trial  	 NN	I-NP
which  	which  	 WDT	O
will  	will  	 MD	O
include  	include  	 VB	O
100  	100  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NN	I-NP
is  	is  	 VBZ	O
freedom  	freedom  	 NN	O
from  	from  	 IN	O
all-cause  	all-cause  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
at  	at  	 IN	O
30  	30  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
22  	22  	 CD	O
Fr  	Fr  	 NNP	B-NP
DFM  	DFM  	 NNP	I-NP
valve  	valve  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
successfully  	successfully  	 RB	O
assessed  	assessed  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
first-in-man  	first-in-man  	 JJ	B-NP
feasibility  	feasibility  	 NN	I-NP
and  	and  	 CC	O
safety  	safety  	 NN	O
trial 	trial 	 NN	O
.  	.  	 .	O
Up  	Up  	 RB	O
to  	to  	 TO	O
three-year  	three-year  	 JJ	B-NP
follow-up  	follow-up  	 NN	I-NP
sustained  	sustained  	 VBD	O
clinical  	clinical  	 JJ	B-NP
benefit  	benefit  	 NN	I-NP
and  	and  	 CC	O
haemodynamic  	haemodynamic  	 JJ	B-NP
performance  	performance  	 NN	I-NP
was  	was  	 VBD	O
demonstrated  	demonstrated  	 VBN	O
with  	with  	 IN	O
no  	no  	 DT	O
or  	or  	 CC	O
trace  	trace  	 JJ	O
aortic  	aortic  	 JJ	B-NP
regurgitation  	regurgitation  	 NN	I-NP
in  	in  	 IN	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
18  	18  	 CD	O
Fr  	Fr  	 NNP	B-NP
DFM  	DFM  	 NNP	I-NP
valve  	valve  	 NN	I-NP
is  	is  	 VBZ	O
under  	under  	 IN	O
investigation  	investigation  	 NN	B-NP
in  	in  	 IN	O
an  	an  	 DT	O
on-going  	on-going  	 JJ	O
trial 	trial 	 NN	O
.  	.  	 .	O
